Diabetes Care
8 articles on Diabetes Care, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Meds: 8 Things to Avoid for Optimal Weight Loss & Health
Navigating weight loss with GLP-1 medications such as semaglutide and tirzepatide requires careful attention to lifestyle choices. This guide details 8 crucial things to avoid to ensure you experience the full benefits and fewer side effects.
8 min read
GLP-1 Revolution: Ozempic's Rise and the Shifting Landscape of Weight Loss
Once primarily a diabetes medication, Ozempic and other GLP-1 agonists have experienced an unprecedented rise in popularity, driven by their significant impact on weight loss. This article delves into the data, the science, and the cultural context behind this revolution.
6 min read
GLP-1 Weight Loss Drugs: Why Eating Habits Matter for Success
New research suggests that the way you eat—whether driven by emotions or external cues—can significantly influence how well GLP-1 medications like Ozempic, Wegovy, and Mounjaro work for weight loss and type 2 diabetes management. Learn what this means for your treatment.
7 min read
Beyond Weight Loss: Understanding GLP-1 Side Effects & Solutions
The rise of GLP-1 medications like Ozempic and Mounjaro has brought significant advancements in weight management and diabetes care. However, as more individuals embrace these therapies, understanding and managing potential side effects becomes crucial for a successful health journey.
7 min read
Beyond 'Ozempic Teeth': Understanding and Managing 'Ozempic Breath'
The rise of GLP-1 medications like Ozempic and Mounjaro has brought about new conversations around their side effects, including the emerging concern of 'Ozempic breath.' This article delves into the causes, implications, and effective management strategies for this common issue.
7 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Eli Lilly's Q1 Surge: GLP-1 Success Fuels Strong Outlook
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
7 min read
Generic GLP-1s: Hope for Affordable Weight Loss & Diabetes Care?
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
7 min read